Observation On The Curative Effect Of Ultrasonic Medicine Permeating Yiqihuoxue Decoction On Epigastric Symptoms Of Patients With Malignant Tumor

Objective: To appraise the clinical efficacy,quality of life and changes in absolute counts of lymphocyte subpopulations in the treatment of gastric symptoms in patients with malignant tumours(Qi deficiency and blood stasis)by ultrasound medicine penetrating Yiqihuoxue decoction in bilateral Zusanli.Investigating the advantages of the bilateral Zusanli acupoint ultrasound medicine penetration to benefit Qi and invigorate Blood formula in the treatment of gastric and epigastric symptoms in patients with malignant tumours(Qi deficiency and blood stasis)and conducting a safety analysis providing more methods and ideas for the treatment of gastric and epigastric symptoms in patients with malignant tumours in Chinese medicine.Methods: A total of 204 cases of malignant tumor patients meeting the standards of intake and discharge were collected by medical record retrieval system and divided into two groups according to the treatment methods.The control group(100 cases)were given basic treatment of western medicine and Chinese medicine decoction.The treatment group(104 cases)were treated by targeted ultrasound drug therapy combined with Yiqi Huoxue Decoction on the basis of control group,once a day,30 minutes each time,14 times in total.Clinical symptoms(stomachpain,stomach distend,nausea,vomiting,and food intake),quality of life score,absolute count of lymphocyte subsets were observed before and after treatment.And the blood routine,D-dimer,blood coagulation function,hepatic and renal function were examined before and after treatment.The data collected were statistically analysed using SPSS 23.0 statistical software: t-tests were used for measurements that conformed to a normal distribution and rank sum tests were used for measurements that did not conform to a normal distribution;chi-square tests or rank sum tests were used for count data.Results: 1.There were no significant differences in gender,age,marital status,occupation, cancer type distribution,TNM stage,previous treatment and pre-treatment KPS score between the two groups(P > 0.05).2.As for the clinical outcomes: The total effective rate of clinical symptom improvement was 89.4% and 73.0% in the treatment and control groups respectively(p=0.04).On the part of total clinical symptom scores,there was no significant variation between the two groups before treatment;the clinical symptom scores of posttreatment of both groups were significantly reduced(P<0.05);when comparing two groups’ symptom scores of posttreatment,the total clinical symptom scores of the treatment group were significantly lower than those of the control group(P <0.01).In the comparison of individual symptoms,nausea,vomiting and food intake were significantly improved in the control group,while stomach pain,nausea,vomiting and food intake were significantly improved in the treatment group.3.Comparison of quality of life: The difference in prior treatment KPS scores between the two groups was not statistically significant(P >0.05)and was comparable.In the between-group comparison,the KPS scores were significantly better in the experimental group than in the control group after treatment(P<0.01).Within group comparison,KPS scores improved in both groups after treatment compared with karnofsky performance status(P <0.05).4.Changes in immune function: Before treatment,CD3+,CD3+CD4+,CD3+CD8+,CD4+/CD8+,CD3-CD19+,CD3-CD16+56+ were not significantly different between the two and were comparable.There were no statistically significant differences in CD3+,CD3+CD4+,CD3+CD8+,CD4+/CD8+,CD3-CD19+,CD3-CD16+56+ in the within-group comparison between after treatment;there was a notable difference in CD3+CD8+ in the between-group comparison(P<0.05).5.Changes in coagulation function: Before treatment,D2,PLT,PT,APTT and FIB were not significantly different between the two groups.After treatment,there was a statistically significant difference between the two groups in terms of PLT(P < 0.05)and in all the remaining items,there were no significant differences.The results of the within-group comparison showed a difference in PLT between the pre-and post-treatment groups(P < 0.05).6.Safety analysis: There were no significant differences in WBC,RBC,HGB,liver and kidney function between the two groups before and after treatment(P > 0.05).Conclusions: 1.The ultrasound-based targeted drug therapy combined with Yiqi Huoxue decoction can significantly improve the epigastric symptoms of malignant tumor patients(qi deficiency and blood stasis syndrome).2.The ultrasound-based targeted drug therapy combined with Yiqi Huoxue decoction can improve the the quality of life of patients with malignant tumor.3.Bilateral Zusanli ultrasound medicine penetrates Yi Qi and invigorates Blood to assist in improving immune function in patients with malignancy.4.The ultrasound-based targeted drug therapy combined with Yiqi Huoxue decoction can significantly It help to improve the hypercoagulability of blood in patients with malignant tumors.5.The ultrasound-based targeted drug therapy combined with Yiqi Huoxue decoction was no obvious impairment of liver or kidney function.